Please use this identifier to cite or link to this item: https://doi.org/10.1038/tpj.2011.7
Title: Translational aspects of genetic factors in the prediction of drug response variability: A case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia
Authors: Chan, S.L.
Suo, C. 
Lee, S.C. 
Goh, B.C.
Chia, K.S. 
Teo, Y.Y. 
Keywords: drug response variability
pharmacogenomics
translational genetics
warfarin
Issue Date: Aug-2012
Citation: Chan, S.L., Suo, C., Lee, S.C., Goh, B.C., Chia, K.S., Teo, Y.Y. (2012-08). Translational aspects of genetic factors in the prediction of drug response variability: A case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics Journal 12 (4) : 312-318. ScholarBank@NUS Repository. https://doi.org/10.1038/tpj.2011.7
Abstract: Genetic markers displaying highly significant statistical associations with complex phenotypes may not necessarily possess sufficient clinical validity to be useful. Understanding the contribution of these markers beyond readily available clinical biomarkers is particularly important in pharmacogenetics. We demonstrate the utility of genetic testing using the example of warfarin in a multi-ethnic setting comprising of three Asian populations that are broadly representative of the genetic diversity for half of the population in the world, especially as distinct interethnic differences in warfarin dose requirements have been previously established. We confirmed the roles of three well-established loci (CYP2C9, VKORC1 and CYP4F2) in explaining warfarin dosage variation in the three Asian populations. In addition, we assessed the relationship between ethnicity and the genotypes of these loci, observing strong correlations at VKORC1 and CYP4F2. Subsequently, we established the additional utility of these genetic factors in predicting warfarin dose beyond ethnicity and clinical biomarkers through performing a series of systematic cross-validation analyses of the relative predictive accuracies of various fixed-dose regimen, clinical and genetic models. Through a pharmacogenetics model for warfarin, we show the importance of genetic testing beyond readily available clinical biomarkers in predicting dose requirements, confirming the role of genetic profiling in personalized medicine. © 2012 Macmillan Publishers Limited. All rights reserved.
Source Title: Pharmacogenomics Journal
URI: http://scholarbank.nus.edu.sg/handle/10635/109125
ISSN: 1470269X
DOI: 10.1038/tpj.2011.7
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

18
checked on Jul 19, 2018

WEB OF SCIENCETM
Citations

14
checked on Jul 3, 2018

Page view(s)

107
checked on Jun 8, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.